WT1-sensitized T cells
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia
Conditions
Leukemia, Myelodysplastic Syndrome
Trial Timeline
Feb 8, 2008 → Feb 26, 2021
NCT ID
NCT00620633About WT1-sensitized T cells
WT1-sensitized T cells is a phase 1 stage product being developed by Atara Biotherapeutics for Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00620633. Target conditions include Leukemia, Myelodysplastic Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00620633 | Phase 1 | Completed |
Competing Products
20 competing products in Leukemia